Table 2.
Periprocedural characteristics of included studies
| Study | Year | Preprocedural imaging | Target ACT (s) | Radiofrequency ablation (%) | Protamine use (%) | Resumption of oral anticoagulation therapy |
|---|---|---|---|---|---|---|
| Ando18 | 2019 | TOE | 300–350 | 0 | 100 | Evening after procedure |
| Nagao19 | 2019 | TOE/CT | 300 | 100 | 100 | Evening after procedure (A) or morning after procedure (R + E) |
| Nakamura20 | 2019 | NR | 300–350 | 0 | NR | Evening after procedure (uninterrupted group) or morning after procedure (minimally interrupted group) |
| Reynolds9 | 2018 | TOE (46%) | >300 | 52 | 90 | Evening after procedure |
| Vlachos21 | 2017 | TOE | 300–400 | 100 | NR | Evening after procedure |
| Yamaji22 | 2019 | NR | 300–400 | 100 | 100 | Evening after procedure (A + D) or morning after procedure (R + E) |
| Yoshimura10 | 2017 | TOE | >300 | 100 | NR | NR |
| Yu23 | 2018 | TOE/ICE | 350–400 | 100 | NR | Evening after procedure |
A, apixaban; ACT, activated clotting time; CT, computed tomography; D, dabigatran; E, edoxaban; ICE, intracardiac echography; NR, not reported; R, rivaroxaban; TOE, transesophageal echocardiography.